vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Armour Residential REIT, Inc. is the larger business by last-quarter revenue ($50.4M vs $34.1M, roughly 1.5× Karyopharm Therapeutics Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -299.9%, a 720.1% gap on every dollar of revenue. On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs 11.6%). Over the past eight quarters, Armour Residential REIT, Inc.'s revenue compounded faster (108.0% CAGR vs 1.4%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
ARR vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $34.1M |
| Net Profit | $211.7M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | — | -52.4% |
| Net Margin | 420.2% | -299.9% |
| Revenue YoY | 297.9% | 11.6% |
| Net Profit YoY | 555.9% | -232.0% |
| EPS (diluted) | $2.43 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $34.1M | ||
| Q3 25 | $38.5M | $44.0M | ||
| Q2 25 | $33.1M | $37.9M | ||
| Q1 25 | $36.3M | $30.0M | ||
| Q4 24 | $12.7M | $30.5M | ||
| Q3 24 | — | $38.8M | ||
| Q2 24 | $7.0M | $42.8M | ||
| Q1 24 | — | $33.1M |
| Q4 25 | $211.7M | $-102.2M | ||
| Q3 25 | $159.3M | $-33.1M | ||
| Q2 25 | $-75.6M | $-37.3M | ||
| Q1 25 | $27.3M | $-23.5M | ||
| Q4 24 | $-46.4M | $-30.8M | ||
| Q3 24 | — | $-32.1M | ||
| Q2 24 | $-48.4M | $23.8M | ||
| Q1 24 | — | $-37.4M |
| Q4 25 | — | -52.4% | ||
| Q3 25 | — | -34.6% | ||
| Q2 25 | — | -64.3% | ||
| Q1 25 | — | -110.8% | ||
| Q4 24 | — | -102.4% | ||
| Q3 24 | — | -67.8% | ||
| Q2 24 | — | -65.7% | ||
| Q1 24 | — | -101.9% |
| Q4 25 | 420.2% | -299.9% | ||
| Q3 25 | 413.5% | -75.2% | ||
| Q2 25 | -228.4% | -98.2% | ||
| Q1 25 | 75.2% | -78.2% | ||
| Q4 24 | -366.8% | -100.8% | ||
| Q3 24 | — | -82.7% | ||
| Q2 24 | -693.8% | 55.6% | ||
| Q1 24 | — | -112.8% |
| Q4 25 | $2.43 | $-7.02 | ||
| Q3 25 | $1.49 | $-3.82 | ||
| Q2 25 | $-0.94 | $-4.32 | ||
| Q1 25 | $0.32 | $-2.77 | ||
| Q4 24 | $-0.91 | $-2.33 | ||
| Q3 24 | — | $-3.85 | ||
| Q2 24 | $-1.05 | $-2.97 | ||
| Q1 24 | — | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $-292.9M |
| Total Assets | $21.0B | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $60.5M | ||
| Q3 25 | $44.2M | $37.7M | ||
| Q2 25 | $141.2M | $38.7M | ||
| Q1 25 | $49.1M | $38.8M | ||
| Q4 24 | $68.0M | $62.5M | ||
| Q3 24 | — | $72.8M | ||
| Q2 24 | $126.6M | $84.8M | ||
| Q1 24 | — | $30.6M |
| Q4 25 | $2.3B | $-292.9M | ||
| Q3 25 | $2.1B | $-269.3M | ||
| Q2 25 | $1.7B | $-238.9M | ||
| Q1 25 | $1.7B | $-205.9M | ||
| Q4 24 | $1.4B | $-186.0M | ||
| Q3 24 | — | $-159.6M | ||
| Q2 24 | $1.2B | $-132.1M | ||
| Q1 24 | — | $-169.0M |
| Q4 25 | $21.0B | $108.4M | ||
| Q3 25 | $19.4B | $96.2M | ||
| Q2 25 | $16.2B | $104.9M | ||
| Q1 25 | $15.5B | $127.7M | ||
| Q4 24 | $13.5B | $164.4M | ||
| Q3 24 | — | $189.5M | ||
| Q2 24 | $10.1B | $214.0M | ||
| Q1 24 | — | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $-11.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $-11.8M | ||
| Q3 25 | $-37.8M | $-5.9M | ||
| Q2 25 | $25.0M | $-18.7M | ||
| Q1 25 | $101.5M | $-39.0M | ||
| Q4 24 | $261.5M | $-25.8M | ||
| Q3 24 | — | $-19.5M | ||
| Q2 24 | $27.1M | $-38.5M | ||
| Q1 24 | — | $-43.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-43.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -84.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -132.6% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARR
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
